Black Swan Sale

50% Off Elite

Days

Hours

Mins

Sec

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

EQ

Equillium Inc

Dec 01 • 04:00PM ET

0.8600

-0.0424 -4.70 %

Healthcare • Biotechnology • USA • NASD

Peers: ATRA LGND CLDX FATE ANAB ADMA BDTX KNSA CRBP CYCN

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.63	Insider Own	29.18%	Shs Outstand	60.68M	Perf Week	-10.42%
Market Cap	52.37M	Forward P/E	-	EPS next Y	-0.24	Insider Trans	-0.05%	Shs Float	43.13M	Perf Month	-39.44%
Enterprise Value	19.99M	PEG	-	EPS next Q	-0.05	Inst Own	38.56%	Short Float	1.74%	Perf Quarter	-50.00%
Income	-24.42M	P/S	11.93	EPS this Y	-86.96%	Inst Trans	25.52%	Short Ratio	0.95	Perf Half Y	134.97%
Sales	4.39M	P/B	1.69	EPS next Y	44.19%	ROA	-70.81%	Short Interest	0.75M	Perf YTD	14.94%
Book/sh	0.51	P/C	1.58	EPS next 5Y	1.47%	ROE	-90.24%	52W High	2.35 -63.40%	Perf Year	10.27%
Cash/sh	0.54	P/FCF	-	EPS past 3/5Y	44.79% 31.13%	ROIC	-77.73%	52W Low	0.27 218.52%	Perf 3Y	-48.81%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	97.09%	Volatility	12.26% 14.08%	Perf 5Y	-83.62%
Dividend TTM	-	EV/Sales	4.55	EPS Y/Y TTM	-382.07%	Oper. Margin	-554.90%	ATR (14)	0.13	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.85	Sales Y/Y TTM	-90.43%	Profit Margin	-555.94%	RSI (14)	35.55	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	10.85	EPS Q/Q	-32300.00%	SMA20	-18.30%	Beta	1.92	Target Price	4.00
Payout	-	Debt/Eq	0.02	Sales Q/Q	-100.00%	SMA50	-31.67%	Rel Volume	0.25	Prev Close	0.90
Employees	35	LT Debt/Eq	0.02	Earnings	Nov 13 AMC	SMA200	1.84%	Avg Volume	795.31K	Price	0.86
IPO	Oct 12, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	14.29% -	Trades		Volume	201,392	Change	-4.70%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-28-25	Downgrade	Leerink Partners	Outperform → Market Perform	$3 → $1
Oct-29-21	Resumed	Stifel	Buy	$12
Sep-15-21	Initiated	Cantor Fitzgerald	Overweight	$14
Jul-14-20	Reiterated	H.C. Wainwright	Buy	$14 → $24
Jul-10-20	Resumed	Stifel	Buy	$22 → $10
Feb-22-19	Initiated	SVB Leerink	Outperform	$16

Nov-20-25 04:35PM	Equillium to Participate in Upcoming Investor Conferences (GlobeNewswire)
07:30AM	The Zacks Analyst Blog Highlights MS, VOO, SPY, IVV, SPYM, RSP, EQ and EQWL (Zacks)
Nov-13-25 04:05PM	Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update (GlobeNewswire) -9.09% +23.81%
Nov-04-25 08:30AM	Equillium to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.10%
Nov-03-25 04:05PM	Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.93%
03:56AM	Loading…
Oct-27-25 03:56AM	Cipla's flagship respiratory initiative Breathefree broadens its footprint in the UAE (PR Newswire)
Oct-22-25 08:00AM	Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025 (GlobeNewswire) -6.52%
Oct-06-25 04:02PM	Equillium Announces Leadership and Corporate Updates (GlobeNewswire) +12.78%
Sep-03-25 04:05PM	Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.72% -6.42%
07:30AM	These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025 (Motley Fool)
Aug-29-25 04:03PM	Equillium to Participate in the Cantor Global Healthcare Conference 2025 (Business Wire)
Aug-11-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +78.88%
08:30AM	Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic (Business Wire)
Aug-04-25 08:30AM	Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy (Business Wire) -20.66%
Aug-01-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +81.59%
08:00AM	Loading…
May-06-25 08:00AM	Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists (Business Wire) -8.15%
May-01-25 08:00AM	Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504 (Business Wire)
Apr-24-25 09:00AM	Equillium Announces Feedback from the U.S. Food and Drug Administration (Business Wire)
Apr-01-25 09:55AM	Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks) +28.42%
Mar-27-25 12:49PM	Equillium pushes for breakthrough status despite missing primary endpoint (Clinical Trials Arena) -35.62%
07:00AM	Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights (Business Wire)
07:00AM	Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease (Business Wire)
Feb-21-25 09:55AM	Here's Why Equillium (EQ) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Feb-10-25 12:00PM	Equillium (EQ) Upgraded to Buy: Here's What You Should Know (Zacks) -10.10%
08:50AM	Equillium (EQ) Shows Fast-paced Momentum But Is Still a Bargain Stock (Zacks)
Feb-06-25 04:18PM	Equillium Reports Positive Phase 2 Results for Itolizumab in Ulcerative Colitis, Shares Surge (GuruFocus.com) +33.03% -9.31%
08:00AM	Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis (Business Wire)
Nov-13-24 04:01PM	Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates (Business Wire) -8.18% -12.33%
08:00AM	Equillium to Present at the Stifel Healthcare Conference (Business Wire)
Nov-12-24 08:00AM	Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer (Business Wire) +13.24%
10:00AM	Loading…
Nov-06-24 10:00AM	Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth (Zacks)
Oct-31-24 07:00AM	Equillium Maintains Rights to Itolizumab Following Ono Partnership (Business Wire) -37.61%
Oct-07-24 08:00AM	Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (Business Wire) +8.00%
Sep-17-24 11:54AM	Equillium collaborates with Vivtex for oral formulation of autoimmune therapy (Pharmaceutical Technology)
Sep-10-24 08:00AM	Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit (Business Wire)
Sep-04-24 08:00AM	Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-28-24 08:00AM	Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference (Business Wire)
Aug-08-24 05:35PM	Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates (Zacks)
04:01PM	Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights (Business Wire)
Aug-06-24 08:00AM	Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease (Business Wire) +14.85%
Jul-18-24 01:57PM	Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance (Business Wire)
Jul-02-24 08:00AM	Equillium to Participate in Upcoming Investor Conferences (Business Wire)
Jun-12-24 08:00AM	Equillium to be included in the Russell Microcap Index (Business Wire)
Jun-05-24 08:00AM	Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -19.08%
Jun-04-24 08:00AM	Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata (Business Wire) -27.89%
May-29-24 08:00AM	Equillium to Present at the Jefferies Global Healthcare Conference (Business Wire) -5.48%
May-14-24 08:00AM	Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease (Business Wire)
May-09-24 10:56PM	EQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +5.88% -15.00%
05:35PM	Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights (Business Wire)
May-07-24 08:00AM	Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists (Business Wire)
Apr-03-24 08:00AM	Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.88%
Apr-01-24 10:15AM	Equillium's lupus drug improves kidney biomarker, teeing up opt-in decision from Ono (FierceBiotech.com) -8.66%
08:00AM	Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis (Business Wire)
Mar-25-24 09:53PM	EQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -13.48% -15.57%
05:10PM	Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights (Business Wire)
Mar-22-24 08:00AM	Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference (Business Wire)
Jan-29-24 04:07AM	15 Cash-Rich Penny Stocks Hedge Funds Are Buying (Insider Monkey)
Dec-21-23 09:52AM	Equillium swaps multi-cytokine inhibitor for oral option after underwhelming phase 2 data (FierceBiotech.com) -9.57%
08:00AM	Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease (Business Wire)
Nov-20-23 11:23AM	EQ Bank Card launches in Québec as Carte Banque EQ (PR Newswire)
Nov-13-23 09:00AM	Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology (Business Wire)
Nov-08-23 04:01PM	Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates (Business Wire)
Nov-06-23 08:00AM	Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology (Business Wire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE) -7.52%
Oct-19-23 08:00AM	Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology (Business Wire)
Oct-16-23 08:00AM	Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium (Business Wire) +6.66%
Oct-03-23 08:00AM	Equillium to Host Analyst & Investor Day (Business Wire)
Oct-02-23 08:00AM	Equillium to Present at the JonesTrading 2023 Healthcare Summit (Business Wire)
Sep-20-23 08:00AM	Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences (Business Wire)
Aug-30-23 08:00AM	Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference (Business Wire)
Aug-12-23 08:05AM	Equillium, Inc. (NASDAQ:EQ) Just Reported, And Analysts Assigned A US$6.06 Price Target (Simply Wall St.)
Aug-09-23 05:30PM	Equillium, Inc. (EQ) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates (Business Wire)
Aug-02-23 04:00PM	Equillium Announces $7.5 Million Share Repurchase Program (Business Wire)
Jun-01-23 08:00AM	Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences (Business Wire)
May-15-23 08:00AM	Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists (Business Wire) +16.84%
May-11-23 05:25PM	Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates (Business Wire)
May-03-23 06:14AM	News Flash: Analysts Just Made A Meaningful Upgrade To Their Equillium, Inc. (NASDAQ:EQ) Forecasts (Simply Wall St.)
Apr-24-23 08:00AM	Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation (Business Wire)
Mar-23-23 04:01PM	Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates (Business Wire) +11.54%
Mar-22-23 08:00AM	Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference (Business Wire)
Feb-17-23 08:00AM	Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR (Business Wire)
Feb-07-23 08:00AM	Equillium to Present at the SVB Securities Annual Global Healthcare Conference (Business Wire)
Jan-13-23 08:00AM	Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Business Wire) -6.78%
Dec-23-22 04:01PM	Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement (Business Wire) -5.62%
Dec-16-22 08:00AM	Equilliums Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis (Business Wire)
Dec-06-22 12:17PM	Autoimmune Biotech Scores $26M Payment, Up To $139M To Advance Phase 3 Research (Benzinga)
07:00AM	Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab (Business Wire)
Nov-14-22 04:01PM	Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates (Business Wire) +5.35%
08:00AM	Equillium Announces Data Suggesting Soluble ALCAM as a Potential Biomarker of Disease Severity in Lupus Nephritis at ACR Convergence 2022 (Business Wire)
Nov-10-22 08:00AM	Equillium Announces Initiation of Phase 2 study of EQ101 A First-in-Class Multi-Cytokine Inhibitor of IL-2, IL-9 and IL-15 Targeting Alopecia Areata (Business Wire)
Nov-08-22 08:00AM	Equillium to Present at Two Upcoming Investor Conferences (Business Wire)
Nov-03-22 08:00AM	Equillium Announces Presentation at the 6th Annual Dermatology Drug Development Summit (Business Wire)
Nov-02-22 08:00AM	Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease (Business Wire)
Oct-26-22 08:00AM	Equillium Announces Presentation of Data Demonstrating Biological Importance of Multi-Cytokine Inhibitors EQ101 and EQ102 at the La Jolla Immunology Conference (Business Wire)
Sep-27-22 08:15AM	Equillium's stock is up 12% after sharing early data about its investigational lupus treatment (MarketWatch) +22.80%
08:04AM	Equillium Shares Ride Higher After Positive Data From Lead Asset In Kidney Inflammation (Benzinga)

Equillium, Inc. is a clinical-stage biotechnology company that engages in the development of novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly in March 2017 and is headquartered in La Jolla, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zedelmayer Christine	Sr. Vice President and COO	Nov 25 '25	Sale	0.95	8,098	7,696	127,148	Nov 25 06:08 PM
Zedelmayer Christine	Officer	Nov 25 '25	Proposed Sale	0.92	8,098	7,428		Nov 25 02:43 PM
Keyes Jason A	Former CFO	Jul 07 '25	Proposed Sale	0.32	88,913	28,452		Jul 08 10:50 AM
THE KEYES TRUST U/A DTD 09/10/	Director	Jun 12 '25	Proposed Sale	0.39	10,000	3,860		Jun 12 04:19 PM
Keyes Jason A	Chief Financial Officer	Jan 23 '25	Sale	0.65	10,000	6,500	37,720	Jan 24 06:37 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

EQ

Equillium Inc

Upgrade your FINVIZ experience